Black Diamond Therapeutics (BDTX) Capital Expenditures (2019 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Capital Expenditures came in at $256000.0 in Q2 2026, up 681.82% on a YoY basis from $32744.2 in Q2 2025, and up 681.82% quarter-over-quarter from -$44000.0 in Q1 2026.
Powered by 
Analysis
Black Diamond Therapeutics (BDTX) Capital Expenditures (2019 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has reported Capital Expenditures for 8 consecutive years, with $256000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Capital Expenditures rose 681.82% year-over-year to $256000.0; the trailing twelve-month figure through Jun 2026 stood at $124000.0 (up 170.45% YoY), and the FY2025 full-year result was -$176000.0, down 170.68% from the prior year.
- Capital Expenditures rose to $256000.0 in Q2 2026 per BDTX's latest filing, from -$44000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $337000.0 in Q2 2024 and bottomed at -$44000.0 in Q3 2024.
- Historically, Capital Expenditures has averaged $39230.8 across 5 years, with a median of -$44000.0 in 2024.
- The sharpest annual moves came in 2024 and 2026: Capital Expenditures slumped 233.33% in 2024, then soared 681.82% in 2026.
- Over 5 years, Capital Expenditures stood at -$8000.0 in 2022, then soared by 512.5% to $33000.0 in 2023, then plunged by 233.33% to -$44000.0 in 2024, then changed by 0.0% to -$44000.0 in 2025, then jumped by 681.82% to $256000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $256000.0, -$44000.0, and -$44000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 37.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -1.87 Mn |
| 10 | Black Diamond Therapeutics | 111.58 Mn | 1.07 Mn | - | 256,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 256,000.00 |
| Mar 31, 2026 | -44,000.00 |
| Dec 31, 2025 | -44,000.00 |
| Sep 30, 2025 | -44,000.00 |
| Jun 30, 2025 | -44,000.00 |
| Mar 31, 2025 | -44,000.00 |
| Dec 31, 2024 | -44,000.00 |
| Sep 30, 2024 | -44,000.00 |
| Jun 30, 2024 | 337,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Sep 30, 2022 | -8,000.00 |
| Jun 30, 2022 | 193,000.00 |
| Mar 31, 2022 | 7,000.00 |
| Dec 31, 2021 | 333,000.00 |
| Sep 30, 2021 | 1.18 Mn |
| Jun 30, 2021 | 814,000.00 |
| Mar 31, 2021 | 385,000.00 |
| Dec 31, 2020 | 109,000.00 |
| Sep 30, 2020 | 8,000.00 |
| Jun 30, 2020 | 5,000.00 |